- Home
- FIG vs ARWR Comparison
FIG vs ARWR Comparison
Compare FIG & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | ARWR |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.4B |
| IPO Year | 2025 | 2009 |
Fundamental Metrics
Financial Performance| Metric | FIG | ARWR |
|---|---|---|
| Price | $27.27 | $88.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $50.50 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 18.6M | 1.3M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.80 | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,055,788,000.00 | $16,142,321.00 |
| Revenue This Year | $31.18 | N/A |
| Revenue Next Year | $20.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.96 | N/A |
| 52 Week Low | $16.60 | $21.06 |
| 52 Week High | $71.41 | $95.49 |
Technical Indicators
Market Signals| Indicator | FIG | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 57.90 |
| Support Level | $26.79 | $82.70 |
| Resistance Level | $28.11 | $90.97 |
| Average True Range (ATR) | 1.55 | 2.61 |
| MACD | 0.10 | -0.24 |
| Stochastic Oscillator | 83.70 | 77.61 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.